Ditto Biosciences

Ditto Biosciences (Ditto Bio) is a San Francisco biotechnology startup, founded in 2025 and backed by Y Combinator (Winter 2026 batch), that discovers drugs for autoimmune diseases by identifying and engineering immune-controlling proteins that parasites, viruses, ticks, and worms have naturally evolved over millions of years to modulate the human immune system. The company pairs an AI platform with wet-lab biology to mine more than a million natural proteins, identify candidates predicted to hit clinically validated human immune-disease targets, and transform them into therapeutic candidates. Ditto is an early-stage, three-person team led by founders Dennis Sun (CEO), Adair Borges (CSO), and Emily Weiss (CTO). This is a company profile in the API Evangelist network; Ditto Bio currently publishes a marketing and science website only and exposes no public API, developer portal, SDK, or machine-readable developer surface.

Ditto Biosciences is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Drug Discovery, Autoimmune Disease, and Immunology.

Ditto Biosciences’ developer surface includes engineering blog, support, and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyDrug DiscoveryAutoimmune DiseaseImmunologyTherapeuticsArtificial IntelligenceProteinsY Combinator

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 8.1/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/ditto-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Company 4

The organization behind the API

Website

Website

Blog

Blog

LinkedIn

Twitter

Twitter

Other 1

Properties that don't map to a standard resource type

Publications

Publications

Source (apis.yml)

aid: ditto-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/ditto-biosciences.png
name: Ditto Biosciences
description: Ditto Biosciences (Ditto Bio) is a San Francisco biotechnology startup, founded in 2025 and backed by Y Combinator
  (Winter 2026 batch), that discovers drugs for autoimmune diseases by identifying and engineering immune-controlling proteins
  that parasites, viruses, ticks, and worms have naturally evolved over millions of years to modulate the human immune system.
  The company pairs an AI platform with wet-lab biology to mine more than a million natural proteins, identify candidates
  predicted to hit clinically validated human immune-disease targets, and transform them into therapeutic candidates. Ditto
  is an early-stage, three-person team led by founders Dennis Sun (CEO), Adair Borges (CSO), and Emily Weiss (CTO). This is
  a company profile in the API Evangelist network; Ditto Bio currently publishes a marketing and science website only and
  exposes no public API, developer portal, SDK, or machine-readable developer surface.
url: https://raw.githubusercontent.com/api-evangelist/ditto-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- y-combinator
x-tier: stub
x-tier-reason: portfolio-lead
x-yc-batch: W26
x-founded: '2025'
x-location: San Francisco, CA
x-industry: Biotechnology
x-founders:
- Dennis Sun (CEO)
- Adair Borges (CSO)
- Emily Weiss (CTO)
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biotechnology
- Drug Discovery
- Autoimmune Disease
- Immunology
- Therapeutics
- Artificial Intelligence
- Proteins
- Y Combinator
apis: []
common:
- type: DomainSecurity
  url: security/ditto-biosciences-domain-security.yml
- type: Website
  url: https://www.dittobio.com/
- type: Blog
  url: https://www.dittobio.com/blog
- type: Publications
  url: https://www.dittobio.com/science
- type: Support
  url: mailto:hello@dittobio.com
- type: LinkedIn
  url: https://www.linkedin.com/company/dittobio
- type: Twitter
  url: https://x.com/dittobio
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence